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Abstract
Background: TMPRSS2:ERG gene aberration may be a novel marker that improves risk stratification of prostate
cancer before definitive cancer therapy, but studies have been inconclusive.
Methods: The study cohort consisted of 202 operable prostate cancer Slovenian patients who underwent laparoscopic
radical prostatectomy. We retrospectively constructed tissue microarrays of their prostatic specimens for fluorescence in
situ hybridization, with appropriate signals obtained in 148 patients for subsequent statistical analyses.
Results: The following genetic aberrations were found: TMPRSS2:ERG fusion, TMPRSS2 split (a non-ERG translocation)
and ERG split (an ERG translocation without involvement of TMPRSS2). TMPRSS2:ERG gene fusion happened in 63
patients (42 %), TMPRSS2 split in 12 patients and ERG split in 8 patients. Association was tested between TMPRSS2:ERG
gene fusion and several clinicopathological variables, i.e., pT stage, extended lymph node dissection status, and Gleason
score, correcting for multiple comparisons. Only the association with pT stage was significant at p = 0.05: Of 62 patients
with pT3 stage, 34 (55 %) had TMPRSS2:ERG gene fusion. In pT3 stage patients, stronger (but not significant) association
between eLND status and TMPRSS2:ERG gene fusion was detected. We detected TMPRSS2:ERG gene fusion in 64 % of
the pT3 stage patients where we did not perform an extended lymph node dissection.
Conclusions: Our results indicate that it is possible to predict pT3 stage at final histology from TMPRSS2:ERG gene
fusion at initial core needle biopsy. FISH determination of TMPRSS2:ERG gene fusion may be particularly useful for
patients scheduled to undergo a radical prostatectomy in order to improve oncological and functional results.
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Background
Prostate cancer (PCa) is the most common cancer in
males and one of the major leading causes of morbidity
and mortality. The incidence is higher in Western
Europe (>200 per 100,000) than in Eastern Europe [1].
With the widespread use of serum prostatic specific
antigen (PSA) screening, almost 90 % of PCa cases can
be diagnosed. On the other hand, screening is associated
with overdiagnosis and overtreatment with an impact on
the patient’s quality of life [2, 3]. Whether underesti-
mated clinically localized cancers should be treated, and
if treated, how aggressively they should be treated, remains
an important management dilemma. The clinical stage,
Gleason grade and the serum PSA levels are used for prog-
nosis and treatment stratification at the time of diagnosis.
However, these indicators do not always accurately predict
a clinical outcome on an individual patient basis [4]. Thus,
more specific diagnostic modalities, prognostic indicators
of progression and a better understanding of PCa biology
are high priorities in PCa research [5].
The identification of the common TMPRSS2:ERG gene
fusion in PCa could enable us to detect the disease in an
earlier stage and also make it possible to design the proper
therapy for each patient. With that we could predict
disease outcomes [5, 6], more easily. In this study we
examined potential associations between TMPRSS2:ERG
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gene fusion and clinicopathological characteristics with
the aim of helping predict the cancer outcome.
Methods
Study population
The study cohort consisted of 202 operable PCa patients
who underwent laparoscopic radical prostatectomy at
the General Hospital Slovenj Gradec in Slovenia, but only
148 patients yielded appropriate signals for futher analysis.
Patients were operated in the period between January
2010 and July 2011. Conventional clinicopathological data
were evaluated. The mean age of the patients at the time
of diagnosis was 64 years (range 47–78) years. The mean
value of PSA before operation (Op) was 8.7 ng/ml (range
0.1–110). Extended lymph node dissection (eLND) was
performed in 26 patients (13 %), 8 of which had positive
lymph nodes (N1) and 18 had no tumor metastasis (N0).
The median follow-up time of patients was 36 months.
Fifteen patients experienced a biochemical recurrence and
underwent hormonal therapy. Up until July 2015, none of
these patients had died.
Generation of tissue microarrays (TMA)
The original haematoxylin and eosin (H&E) slides and
paraffin-embedded tumour tissues were retrieved from
the archives of the Department of Pathology, General
Hospital Slovenj Gradec. H&Estained slides of tumour
tissue were reviewed by two pathologists to identify
representative tumour regions without necrosis or pros-
tatic intraepithelial neoplasia. Three tissue cylinders with
a diameter of 0.6 mm were obtained for each corre-
sponding tumour block and arrayed into a recipient new
paraffin block using the tissue chip microarrayer
(Beecher Instruments, Silver Spring, MD). Thirty-nine
recipient tissue blocks were constructed. The blocks
were subsequently cut into 2_3 μm sections and fixed
on silanized glass slides (Knittel Glaeser, Germany) to
support adhesion of the tissue samples for subsequent
fluorescence in situ hybridization (FISH) analysis.
Interphase
Interphase FISH was performed using the ZytoLight® SPEC
ERG/TMPRSS2 TriChech™ DNA Probe (ZytoVision
GmbH, Bremerhaven, Germany), designed to detect dele-
tions between the ERG and TMPRSS2 genes at 21q22 and
other translocations affecting either of these genes. FISH
was performed on pretreated slides (that had undergone
dewaxing, proteolysis, and post-fixation) using the Vysis
Paraffin Pretreatment Reagent Kit (Abbott Molecular Inc.,
Des Plaines, IL, USA), following the manufacturer's
instructions. Slides were denatured in 70 % formamide for
10 min at 73 °C, and the probe was denatured for 10 min
at 75 °C. The probe was applied to each slide and the slide
was covered by a 2–22 mm plastic coverslip and
hybridized overnight in a moist chamber at 37 °C. After
16 h, the coverslips were gently removed, and slides were
washed in 0.4 × saline sodium citrate (SSC) 0.05 % Tween
for 2 min at 73 °C and 2 × SSC 0.05 % Tween for 2–60 s at
RT. The cells were counterstained with 4',6-diamidino-2-
phenylindole (DAPI) and embedded in an antifade
solution. Images were acquired using a Zeiss Axioplan 2
microscope (Goettingen, Germany) equipped with Chroma
optical filters (Chroma Technologies, Brattleboro, VT).
The FISH results were evaluated by two independent
screeners using a 63× objective. In normal interphase
nuclei, two red/green/blue fusion signals were ex-
pected, representing two normal (non-rearranged)
21q22.13-q22.3 loci.
Statistical analysis
We tested significance of the association between several
nominal clinicopathological variables (i.e., pT stage,
eNLD status, Gleason score) and TMPRSS2:ERG fusion.
For this purpose, we used Fisher’s exact test for two-by-
two contingency tables, as well as its Freeman-Halton
extension for two-rows by three-columns contingency
tables, as appropriate. The significance level was set at
0.05. To correct for the multiple tests, we used Bonferroni
correction: Since we test a total of 4 hypotheses (the
association of eNLD and TMPRSS2:ERG fusion on the
subpopulation of pT3 stage patients), the corrected
significance level for the individual hypotheses is set to
0.0125. For a significance level of 0.1, the corrected
significance level for the individual hypotheses would
be 0.025.
Results
We performed FISH analyses on 202 operable PCa
patients. The sample was classified as aberrant if a staining
pattern other than two red/green/blue fusion signals was
detected in at least 20 cells in the tumor. TMPRSS2:ERG
fusion, in wich the 21q22 locus is affected by a 21q22.2
deletion, was indicated as one red/blue fusion signal and
the loss of one green signal (Fig. 1a). An ERG split without
involvement of TMPRSS2 was indicated by a separated
red signal and green/blue fusion signal (Fig. 1b). A
TMPRRS2 split was indicated by a separated blue signal
and red/green fusion signal (Fig. 1c). Tumor samples with
very weak signals or lack of signals were considered to
provide insufficient results and were not considered for
further analysis. A resulting 148 patients were considered
appropriate for subsequent statistical analysis.
The following genetic aberrations were found in the
samples of the 148 patients: TMPRSS2:ERG fusion,
TMPRSS2 split (a non-ERG translocation) and ERG split
(an ERG translocation without involvement of TMPRSS2).
Samples from 79 patients (53 %) had gene aberrations,
while no aberrations were detected in 69 patients (47 %).
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We found TMPRSS2:ERG gene fusion in 63 patients
(42 %), TMPRSS2 split in 12 patients and ERG split in 8
patients. One patient had both TMPRSS2:ERG gene fusion
and a TMPRSS2 split. In three patients, TMRRSS2:ERG
gene fusion and an ERG split were detected.
Table 1 summarizes the clinicopathological character-
istics of the 148 patients included in the study. Averages
(and counts) are given for all patients, as well as for the
groups with/without aberrations and with/without
TMPRSS2:ERG gene fusion. We tested for significant
differences between TMPRSS2:ERG gene fusion positive
and fusion negative cases in terms of pT stage, N stage
and GS before a surgery (Tables 2, 3, and 4).
The association between TMPRSS2:ERG fusion and pT
stage (with values divided into two groups, pT2 and pT3)
was significant. The exact p-value obtained by Fisher’s
exact test was 0.01, which after the Bonferroni correction
still makes the association significant at the 0.05 level.
From 62 patients with pT3 stage, TMPRSS2:ERG gene
fusion was detected in 34 (55 %) (Table 2).
The association between TMPRSS2:ERG fusion and
Gleason score before operation was not significant. The
exact p-value was 0.19. The contingency table is given in
Table 3. This was obtained by the Freeman-Halton
extension of Fisher’s exact test.
The association between TMPRSS2:ERG fusion and
N stage (eLND status) was examined next, consider-
ing the subgroups of eLND, pN0 and pN1 patients.
In the entire population of 148 patients, the associ-
ation was very weak and thus not significant. The
exact p-value was 0.66 (Table 4). Again, the p-value
was obtained by the Freeman-Halton extension of
Fisher’s exact test.
For further statistical analysis, we considered only the
patients with pT3 stage. We re-examined the association
between TMPRSS2:ERG fusion and N stage in this
subpopulation. Here, the association was much stronger
(exact p-value of 0.02), but not significant at the 0.05
level due to the Bonferroni correction. It is only signifi-
cant at the weaker 0.1 level. In the group of patients on
which we did not perform eLND, we detected
TMPRSS2:ERG gene fusion in 25 patients (64 %).
Discussion
Many new biomarkers have been recently tested to
enhance the accuracy of diagnosis, prediction of stage,
estimation of metastatic potential and biochemical recur-
rence of PCa. So far, only a few have shown positive results
and promising practical use in everyday practice. One of
the most promising biomarkers is TMPRSS2:ERG gene
fusion. This fusion is important not only for its high
prevalence (or combining with other biomarkers), sensitiv-
ity and specificity in early diagnosis of PCa [7, 8], but also
in predicting the stage [9–11], aggressiveness [9, 12] and
metastatic potential of the tumor [11, 13].
In our study of 148 patients, we observed a prevalence of
gene fusion in 42 %, which is similar to published data
reporting prevalence ranges of 44–50 % [14–16]. Futher-
more, we found no differences between fusion positive and
negative cases in relation to age, PSA and GS. This is in
concordance with the study by Magi-Galluzzi et al.
that included 42 Caucasians, 64 African-Americans,
and 44 Japanese patients who underwent radical pros-
tatectomy [17]. TMPRSS2:ERG gene fusion correlated
with ethnicity (p = 0.03) and marginally correlated
with pathologic stage (p = 0.06), but did not correlate
Fig. 1 Three cases of invasive adenocarcinoma of the prostate (H&E, 20×) with corresponding FISH staining. Arrow heads show gene aberration
(split and fusion) and N shows normal signal. a One normal red/green/blue fusion signal and TMPRSS2:ERG fusion as indicated by one red/blue
fusion signal with loss of one green signal. b One normal red/green/blue fusion signal and an ERG split as indicated by one green/blue fusion
signal with the separated red signal. c One normal red/green/blue fusion signal and a TMPRSS2 split as indicated by one red/green fusion signal
with separated blue signal
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with other clinicopathologic parameters, such as age,
preoperative PSA levels, and GS. Pettersson et al. [18]
did not find any statistical significance betveen
TMPRSS2:ERG gene fusion and GS (either low grade
or high grade). Their cohort study includes 1180
patients after radical prostatectomy. with 694 patients
showing GS ≤ 7 and 355 with positive gene rearrange-
ment; a total of 486 patients had poorly differentiated
prostate carcinoma GS ≥8 and 229 patients had gene
fusion (p = 0.58). Similarly, Perner et al. [11] did not
observe any significant associations between GS and
TMPRSS2:ERG status in their study of 118 patients.
Gopalan et al. [19] reported different results. The au-
thors found a statistically significant correlation between
gene fusion and low GS (p = 0.02). Gene fusion was
found in 71 patients (32 %) with GS < 7, 118 patients
(54 %) with GS = 7 and 16 patients (7 %) with GS > 7.
Seventy-four patients (24 %) showed GS < 7, while 182
patients (60 %) with GS = 7 and 40 patients (13 %) with
GS > 7 had no gene fusion.
In the study of Darnel et al. [20] of 196 patients, the
authors found a statistically significant correlation
between TMPRSS2:ERG gene fusion and lower primary
Table 3 Association of Gleason score (before operation) with
gene fusion: Contingency table. The p-value obtained by the
Freeman-Halton extension of Fisher’s exact test for two-by-three
contingency tables is 0.19. After Bonferroni correction for testing
4 hypotheses, this is not significant at the 0.05 level
Gleason score TMPRSS2-ERG No fusion Total
6 21 41 62
7 38 40 78
≥8 4 4 8
Total 63 85 148
Table 1 A summary of the clinico-pathological data of the 148 patients: Overall, with and without gene aberrations and with/
without TMPRSS2:ERG fusion






Patients with no fusion
TMPRSS2:ERG
148 69 79 63 85
pT stage
pT2a 9 5 4 3 6
pT2b 12 7 5 4 8
pT2c 65 34 31 22 43
pT3a 49 20 29 26 23
pT3b 13 3 10 8 5
AGE (years) 64.37 (47–78) 64.50 (47–78) 64.24 (49–76) 64.27 (49–76) 64.44 (47–78)
N stage
eLND 122 57 65 53 69
pN0 18 8 10 6 12
pN1 8 4 4 4 4
PSA before OP (ng/ml) 8.95 (0.1–110) 9.39 (0.1–110) 8.56 (0.71–43.2) 8.37 (0.71–43.2) 9.38 (0.1–110)
GS before OP (N°)
6 62 35 27 21 41
7 78 32 46 38 40
≥8 8 2 6 4 4
PSA 1 month after OP ng/ml 0.26 (0.0–20) 0.42 (0.0–20) 0.11 (0.00–2.8) 0.14 (0.00–2.8) 0.35 (0.001–20)
GS after OP (N°)
6 47 28 19 15 32
7 88 36 52 42 46
≥8 13 5 8 6 7
Table 2 Association of pT (stage) with gene fusion: Contingency
table. The p-value obtained by the Fisher’s exact test for two-by-
two contingency tables is 0.01. After Bonferroni correction for
testing 4 hypotheses, this is still significant at the 0.05 level
TMPRSS2-ERG No fusion Total
pT2 29 57 86
pT3 34 28 62
Total 63 85 148
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Gleason pattern. Gene fusion was detected in 42 % of
patients with primary Gleason pattern 3 and 27 % in
primary Gleason pattern 4 (p = 0.014).
Demichelis et al. [12] showed a statistical
significance between TMPRSS2:ERG gene fusion and
higher GS (p = 0.01). Similar connections between
gene fusion and GS ≥ 8 were shown in study by
Font-Tello et al. [21].
The results of our study show a significant association
between TMPRSS2:ERG gene fusion and pT stage.
Perner S. et al. [11] reported high percentage of
TMPRSS2:ERG rearrangements in patients with pT3
stage, i.e., 50/91 patients (55 %) and p = 0.03. Mehra
et al. [10] reported similar findings for pT2b, but in
the other direction. The authors found a statistically
significant association between TMPRSS2 gene re-
arrangement and the presence of advanced pathologic
tumour stage (p = 0.04), defining advanced stage as
pT2b. In their study, a total of 24 out of 37 (65 %)
patients with positive TMPRSS2 rearrangements had
pathologic tumour stage ≤ pT2b. Font-Tello et al. [21] an-
alyzed the mRNA levels of TMPRSS2-ERG, ERG, PTEN,
and AR (n = 83), as well as ERG immunostaining (n = 78)
in a series of prostate tumors. They found TMPRSS2:ERG
gene fusion in 57 patients and it was associated with stage
T3-T4 tumors. Saramäki et al. [22] did not find correlation
between gene fusion and T3 stage (p = 1.0).
In our study TMPRSS2:ERG gene fusion was twice as
frequent in the group of pT3 patients who did not
undergo eLND compared with the group of pT3 patients
who did undergo eLND. This finding indicates that we
probably underestimate the group of patients with clas-
sical prognostic factors that characterise these patients
as low or intermediate risk of PCa.
As we only had five patients with ERG split alone and
three patients with both ERG split and TMPRSS2:ERG
gene fusion, which was only 10 % of all gene rearrange-
ments, the number of this subgroup was too small for
statistical analyis.
Methodological differences in the patient cohorts
could lead to these discrepancies. Some recent studies
have shown that genetics diferences in prostate cancer
among interracial groups can also be a reason for these
discrepancies [23].
This study had several limitations. The study is retro-
spective in nature and prone to selection and collection
bias. In addition, the sample size was fairly low, limiting
subgroup data analyses. Therefore, all data should be
confirmed in large possible prospective cohorts.
If confirmed in larger studies gene rearrangements on
biopsies or postoperative specimens could be useful
adjunct to clinical routine markers. In addition, it may be
possible to detect these rearrangements in urine samples,
eliminating the need for invasive specimen collection.
Conclusions
Based on our results, we expect that more than half of the
patients with TMPRSS2:ERG gene fusion at their initial
core needle biopsy will have a pT3 stage at their final hist-
ology in more than one half of the cases. This is especially
important for patients with preoperative PSA and GS
values indicating a low or intermediate risk of PCa. For
one half of them, their preoperative clinical stage is prob-
ably underestimated. If, in these patients, we expect a pT3
stage (at their final histology), this could help us to achieve
a lower percentage of positive section margins, as pub-
lished (33.5–66 %) [24]. Namely, in patients with a clinical
pT3 stage, we expect higher prevalence of positive lymph
nodes (7.9–49 %) [24]. Following the results of our present
study, we have to indicate eLND in patients with
confirmed gene fusion, even if they have “false” low risk
PCa (as indicated by their preoperative PSA and GS
values). To conclude, TMPRSS2:ERG gene fusion at the
initial core needle biopsy may be associated with pT3
stage and may therefore represent a biomarker for clinical
routine. FISH determination of TMPRSS2:ERG gene
fusion may be particularly useful for patients scheduled to
undergo a nerve-sparing procedure in order to improve
oncological and functional results. However, it is difficult
to support the theory that patients with gene fusion will
have worse prognosis.
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